Albireo appoints Cooper as CEO
Thursday, September 24, 2015
Ron Cooper has joined Albireo, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH and gastrointestinal disorders, as president and chief executive officer.
Cooper has global biopharmaceutical experience growing businesses, brands and organizations in the U.S. and Europe. He joined Albireo from Bristol-Myers Squibb (BMS), where he was president of Europe. In addition, Albireo has established a U.S. subsidiary office in Boston, Mass.
During his more than 25 years at BMS, Cooper worked in five different countries and held positions of increasing responsibility in sales, marketing and general management, culminating as president of Europe. He was responsible for more than 30 countries with sales exceeding $4.5 billion. While at BMS, he was directly involved with numerous products, including Abilify, Avapro, Atripla, Eliquis, Orencia, Pravachol, Plavix, Reyataz, Sustiva, Sprycel and Yervoy. He has successfully completed more than a dozen business development transactions, including the creation of the first single tablet HIV/AIDS regimen partnership.